
RAW SEQUENCE LISTING ERROR REPORT



#2

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/7/5, 763

Date Processed by STIC: $\frac{12(1/2000)}{12}$

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin30help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 3.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: <u>09/7/5</u>763

1	Wrapped Nucleics	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it.
		Please adjust your right margin to .3, as this will prevent "wrapping".
2	Wrapped Aminos	The amino acid number/lext at the end of each line "wrapped" down to the next line.
		This may occur if your file was retrieved in a word processor after creating it.
		Please adjust your right margin to .3, as this will prevent "wrapping".
3	Incorrect Line Length	The rules require that a line not exceed 72 characters in length. This includes spaces.
		The many be assumed by the same of the
4	Misaligned Amino Acid Numbering	The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
5	Non-ASCII	This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
		Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
6	Variable Length	Sequence(s) contain n's or Xaa's which represented more than one residue.
	·	As per the rules, each n or Xaa can only represent a single residue.
		Please present the maximum number of each residue having variable length and
		indicate in the (ix) feature section that some may be missing.
7	Patentin ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
	J	sequence(s) Normally, Patentin would automatically generate this section from the
		previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
		to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>
		sections for Artificial or Unknown sequences.
8	Skipped Sequences	Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
	(OLD RULES)	(2) INFORMATION FOR SEQ ID NO:X:
		(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
		(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
		This sequence is intentionally skipped
		Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
9	Skipped Sequences	Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
	(NEW RULES)	<210> sequence id number
		\$400> sequence id number 000
·	Use of n's or Xaa's	Use of n's and/or Xaa's have been detected in the Sequence Listing.
	(NEW RULES)	Use of <220> to <223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
		11 (220) to (223) Section, please explain location of it of Xaa, and which residue it of Xaa represents
·	Use of <213>Organism	Sequence(s) are missing this mandatory field or its response.
	(NEW RULES)	
)	Use of <220>Feature	Sequence(s) are missing the <220>Feature and associated headings.
·	(NEW RULES)	Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
	× /	Please explain source of genetic material in <220> to <223> section.
		(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
,	Potentia van 20 mer ii	Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted
· ——	Patentin ver. 2.0 "bug"	Title, Tesalting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
	•	- metree-mid himses G. ameses/ nemena second a condition for the mission of the m

Instead, please use "File Manager" or any other means to copy file to floppy disk.

OIPE

```
DATE: 12/01/2000
                          PATENT APPLICATION: US/09/715,763
                                                                          TIME: 12:13:01
                                                                                                                    Does Not Comply
                                            Diskette Need

John 1.823 & New Seguene Rules, the orly world

Per 1.823 & New Seguene Rules, the orly world

Nemons are: Unknown, Artificial Sequence, or

Genus / Species (sqeetific name)

Gui rower of glanetic nodes

(in 62207-62237

section - see circled

portion of them 12 on

Sun Summan Sheet)

Socitions designated Xaa may be

iide compounds
in the disclosure
                          Input Set : A:\SEQLISTCMX-001.1.txt
                                                                                                             Corrected Diskette Needed
                         Output Set: N:\CRF3\12012000\I715763.raw
        3 <110> APPLICANT: Shashoua, Victor
       5 <120> TITLE OF INVENTION: Compositions and Methods for Counteracting Effects
                 of Reactive Oxygen Species and Free Radicals
       8 <130> FILE REFERENCE: CMX-001.1 US
10 <140> CURRENT APPLICATION NUMBER: US/09/715,763
10 <141> CURRENT FILING DATE: 2000-11-17
      10 <150> PRIOR APPLICATION NUMBER: 60/166,381
      11 <151> PRIOR FILING DATE: 1999-11-18
      13 <160> NUMBER OF SEO ID NOS: 36
      15 <170> SOFTWARE: PatentIn version 3.0
      17 <210> SEQ ID NO: 1
      18 <211> LENGTH: 12
      19 <212> TYPE: PRT
      20 <213> ORGANISM: synthetic
      22 <220> FEATURE:
      23 <221> NAME/KEY
      24 <222> LOCATION
      26 <400> SEQUENCE: 1
      28 Gln Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gln
      29 1
      31 <210> SEO ID NO: 2
      32 <211> LENGTH: 6
      33 <212> TYPE: PRT
      34 <213> ORGANISM: Synthet
      36 <220> FEATURE:
      37 <221> NAME/KEY PEPTIDE
      38 <222> LOCATION:
      40 <400> SEQUENCE: 2
      42 Gln Thr Leu Gln Phe Arg
      43 - 1
      45 <210> SEQ ID NO: 3
      46 <211> LENGTH: 7
      47 <212> TYPE: PRT
      48 <213> ORGANISM (
                            synthet
      50 <220> FEATURE:
      51 <221> NAME/KEY: PEPTIDE
      52 <222> LOCATION:
      53 <223> OTHER INFORMATION: amino acid positions designated Xaa may be
      54
                varied to form alternative peptide compounds
      55
                of the invention, as explained in the disclosure
     /58 <400> SEQUENCE: 3
W 60 Xaa Gly Xaa Xaa Xaa Xaa Xaa
      61 1
      63 <210> SEQ ID NO: 4
      64 <211> LENGTH: 5
      65 <212> TYPE: PRT
      66 <213> ORGANISM: (synthetic
```

RAW SEQUENCE LISTING

 RAW SEQUENCE LISTING
 DATE: 12/01/2000

 PATENT APPLICATION:
 US/09/715,763
 TIME: 12:13:01

Input Set : A:\SEQLISTCMX-001.1.txt
Output Set: N:\CRF3\12012000\1715763.raw

```
68 <220> FEATURE:
                   PEPTIDE
69 <221> NAME/KEY:
70 <222> LOCATION
                   (1)..(5)
72 <400> SEQUENCE
74 Asp Gly Asp Gly Asp
75 1
77 <210> SEQ ID NO: 5
78 <211> LENGTH: 6
79 <212> TYPE: PRT
80 <213> ORGANISM
                   syntheti
82 <220> FEATURE:
83 <221> NAME/KEY/ PEPTIDE
84 <222> LOCATION
                   (1)..(6)
86 <400> SEQUENCE:
88 Asp Gly Asp Gly Phe Ala
89 1
91 <210> SEQ ID NO: 6
92 <211> LENGTH: 7
93 <212> TYPE: PRT
94 <213> ORGANISM: synthetic
96 <220> FEATURE:
97 <221> NAME/KEY PEPTIDE
98 <222> LOCATION: (1) . (7)
100 <400> SEQUENCE: 6
102 Asp Gly Asp Gly Asp Phe Ala
105 <210> SEQ ID NO: 7
106 <211> LENGTH: 7
1.07 <212> TYPE: PRT
108 <213> ORGANISM syntheti
110 <220> FEATURE:
111 <221> NAME/KEY/
                     PEPTIDE
112 <222> LOCATION: (1)..(7
114 <400> SEQUENCE
116 Asp Gly Asn Gly Asp Phe Ala
117 1
119 <210> SEQ ID NO: 8
120 <211> LENGTH: 7
 121 <212> TYPE: PRT
 122 <213> ORGANISM
 124 <220> FEATURE:
 125 <221> NAME/KEY; PEPTIDE
 126 <222> LOCATION (1)..(7)
 128 <400> SEQUENCE: 8
 130 Asn Gly Asn Gly Asp Phe Ala
 1.3.1 1
 133 <210> SEQ TD NO: 9
 134 <211> LENGTH: 7
 135 <212> TYPE: PRT
```

DATE: 12/01/2000

```
PATENT APPLICATION: US/09/715,763
                                                              TIME: 12:13:01
                     Input Set : A:\SEQLISTCMX-001.1.txt
                     Output Set: N:\CRF3\12012000\I715763.raw
    136 <213> ORGANISM: syntheti
     138 <220> FEATURE:
     139 <221> NAME/KEY PEPTIDE
     140 <222> LOCATION:
                         (1)..(7)
     142 <400> SEQUENCE: 9
     144 Asn Gly Asp Gly Asp Phe Ala
     145 1
     147 <210> SEQ 1D NO: 10
     148 <211> LENGTH: 8
     149 <212> TYPE: PRT
     150 <213> ORGANISM synthetic
     152 <220> FEATURE:
     153 <221> NAME/KEY: PEPTIDE
     154 <222> LOCATION: (1)..(8)
     155 <223> OTHER INFORMATION: amino acid positions designated Xaa may be
               varied to form alternative peptide compounds
     156
               of the invention, as explained in the disclosure
     157
     160 <400> SEQUENCE: 10
(W) > 162 Xaa Xaa Met Thr Leu Thr Gln Pro
     163 1
     165 <210> SEQ ID NO: 11
     166 <21.1> LENGTH: 6
     167 <212> TYPE: PRT
     168 <213> ORGANISM synthetic
     170 <220> FEATURE:
     171 <221> NAME/KEY PEPTIDE
     172 <222> LOCATION (1) .. (6)
     174 <400> SEQUENCE: 11
     176 Met Thr Leu Thr Gln Pro
     177 1
     179 <210> SEQ ID NO: 12
     180 <211> LENGTH: 8
     181 <212> TYPE: PRT
     182 <213> ORGANISM: syntheti
     184 <220> FEATURE:
     185 <221> NAME/KEY: CEPTIDE
      186 <222> LOCATION: (1)..(8)
     188 <400> SEQUENCE: 12
     190 Ser Lys Met Thr Leu Thr Gln Pro
     191 1
     193 <210> SEQ ID NO: 13
     194 <211> LENGTH: 6
     195 <212> TYPE: PRT
     196 <213> ORGANISM: synthetic
      198 <220> FEATURE:
      199 <221> NAME/KEY: PEPTIDE
      200 <222> LOCATION:
                          (1)
      202 <400> SEQUENCE: 13
      204 Glu Thr Leu Gln Phe Arg
```

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING

DATE: 12/01/2000 TIME: 12:13:01

PATENT APPLICATION: US/09/715,763

Input Set : A:\SEQLISTCMX-001.1.txt
Output Set: N:\CRF3\12012000\1715763.raw

```
205 1
207 <210> SEQ ID NO: 14
208 <211> LENGTH: 8
209 <212> TYPE: PRT
210 <213> ORGANISM: (synthet
212 <220> FEATURE:
213 <221> NAME/KEY PEPTIDE
214 <222> LOCATION:
216 <400> SEQUENCE: 14
218 Gin Tyr Ser lle Gly Gly Pro Gln
219 1
221 <210> SEQ ID NO: 15
222 <211> LENGTH: 8
223 <212> TYPE: PRT
224 <213> ORGANISM
226 <220> FEATURE:
227 <221> NAME/KEY PEPTIDE
228 <222> LOCATION:
230 <400> SEQUENCE: 15
232 Ser Asp Arg Ser Ala Arg Ser Tyr
233 1
235 <210> SEQ ID NO: 16
236 <211> LENGTH: 12
237 <212> TYPE: PRT
238 <213> ORGANISM: synthetic
240 <220> FEATURE:
241 <221> NAME/KEY PEPTIDE
242 <222> LOCATION: (1) (12)
244 <400> SEQUENCE: 16
246 Asp Gly Asp Gly Asp Phe Ala 11e Asp Ala Pro Glu
247 1
249 <210> SEQ TD NO: 17
250 <211> LENGTH: 5
251 <212> TYPE: PRT
252 <213> ORGANISM: synthet
254 <220> FEATURE:
255 <221> NAME/KEY: PEPTIDE
256 <222> LOCATION: (1)..(5)
 258 <400> SEQUENCE: 17
 260 Asn Gly Asn Gly Asp
261.1
263 <210> SEQ ID NO: 18
 264 <211> LENGTH: 5
 265 <212> TYPE: PRT
 266 <213> ORGANISM: (synthetic
 268 <220> FEATURE:
 269 <221> NAME/KEY (PEPTIDE
 270 <222> LOCATION:
 272 <400> SEQUENCE: 18
```

RAW SEQUENCE LISTING

DATE: 12/01/2000

PATENT APPLICATION: US/09/715,763

TIME: 12:13:01

Input Set : A:\SEQLISTCMX-001.1.txt
Output Set: N:\CRF3\12012000\1715763.raw

```
274 Asp Gly Asn Gly Asp
275 1
277 <210> SEQ ID NO: 19
278 <211> LENGTH: 5
279 <212> TYPE: PRT
280 <213> ORGANISM synthetic
282 <220> FEATURE:
283 <221> NAME/KEY PEPTIDE
284 <222> LOCATION:
                     (1)
286 <400> SEQUENCE: 19
288 Asn Gly Asp Gly Asp
289 1
291 <210> SEQ ID NO: 20
292 <211> LENGTH: 4
293 <212> TYPE: PRT
294 <213> ORGANTSM (synthetic
296 <220> FEATURE:
297 <221> NAME/KEY: PEPTIDE
298 <222> LOCATION:
                     (1): (4)
300 <400> SEQUENCE: 20
302 Asn Gly Asp Gly
303 1
305 <210> SEQ ID NO: 21
306 <211> LENGTH: 6
307 <212> TYPE: PRT
308 <213> ORGANISM synthetic
310 <220> FEATURE:
311 <221> NAME/KEY PEPTIDE
312 <222> LOCATION: (1).
314 <400> SEQUENCE: 21
316 Asn Gly Asn Gly Phe Ala
317 1
31.9 <210> SEQ ID NO: 22
320 <211> LENGTH: 6
 321 <212> IYPE: PRT
322 <213> ORGANISM synthetic
 324 <220> FEATURE:
 325 <221> NAME/KEY PEPTIDE
326 <222> LOCATION: (1)...(6)
 328 <400> SEQUENCE: 22
 330 Asp Gly Asn Gly Phe Ala
 331 1
 333 <210> SEQ ID NO: 23
 334 <211> LENGTH: 6
 335 <212> TYPE: PRT
 336 <213> ORGANISM synthetic
 338 <220> FEATURE:
 339 <221> NAME/KEY: PEPTIDE
 340 <222> LOCATION: (1)..(6)
```

Please edit subsequent sequerer containing this even.

VERIFICATION SUMMARY

DATE: 12/01/2000

PATENT APPLICATION: US/09/715,763

TIME: 12:13:02

Input Set : A:\SEQLISTCMX-001.1.txt
Output Set: N:\CRF3\12012000\1715763.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:60 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 L:423 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:29 L:436 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:30 L:449 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:31 L:462 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:32 L:488 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:34 L:518 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:34 L:518 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:34